SOUTH
SAN FRANCISCO, Calif., March 14,
2023 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced publication of abstracts at the
2023 Annual Meeting of the American Association for Cancer Research
(AACR). IDEAYA will present data for its potential
first-in-class synthetic lethality programs IDE397, a Phase 1/2
methionine adenosyltransferase 2a (MAT2A) inhibitor, IDE161, a
Phase 1/2 poly (ADP-ribose) glycohydrolase (PARG) inhibitor, and
Werner Helicase, for which a development candidate is targeted in
2023.
![(PRNewsfoto/IDEAYA Biosciences, Inc.) (PRNewsfoto/IDEAYA Biosciences, Inc.)](https://mma.prnewswire.com/media/820568/IDEAYA_Logo.jpg)
The abstracts are available online at http://www.aacr.org
in advance of the 2023 Annual Meeting of AACR, which will be held
April 14-19, 2021. The posters will
be available online at https://ir.ideayabio.com/events
following the poster presentations. These data will be
presented by IDEAYA in collaboration with Amgen (IDE397) and GSK
(IDE397, Werner Helicase).
- Abstract 1644: "Dual inhibition of MAT2A and PRMT5 delivers
synergistic anti-tumor responses in preclinical models of
MTAP-deleted cancer" (Fischer, M. et al.)
Date/Time: Monday April 17,
2023 at 9:00 am - 12:30 pm
ET
Session: Experimental and Molecular Therapeutics, Novel
Antitumor Agents 4
Location: Poster Section 18, Poster Board 1
Presenters: IDEAYA, Amgen
- Abstract 1637: "MAT2A inhibition in MTAP-/- tumors confers
mechanistic vulnerabilities to multiple clinically actionable
synthetic lethal drug combinations" (Gerrick, K. et
al.)
Date/Time: Monday April 17,
2023 at 9:00 am – 12:30 pm ET
Session: Experimental and Molecular Therapeutics, Novel
Antitumor Agents 3
Location: Poster Section 17, Poster Board 27
Presenters: IDEAYA, GSK
- Abstract 6093: "IDE161, a potential first-in-class clinical
candidate PARG inhibitor, selectively targets
Homologous-Recombination-Deficient and PARP inhibitor resistant
breast and ovarian tumors" (Abed, M. et al.)
Date/Time: Wednesday April 19,
2023 at 9:00 am - 12:30 pm
ET
Session: Molecular/Cellular Biology and Genetics, Targeting
DNA Damage Response and Novel Pathways
Location: Poster Section 13, Poster Board 1
Presenters: IDEAYA
- Abstract 1628: "A small-molecule inhibitor of WRN
selectively kills MSI-H cancer cells and phenocopies WRN genetic
defects" (Rao, Y. et al.)
Date/Time: Monday April 17,
2023 at 9:00 am - 12:30 pm
ET
Session: Experimental and Molecular Therapeutics, Novel
Antitumor Agents 3
Location: Poster Section 17, Poster Board 18
Presenters: IDEAYA, GSK
"We are excited to present foundational preclinical data
supporting our clinical-stage IDE397 and IDE161 programs and our
preclinical Werner Helicase program. These data include
fundamental mechanistic, biological and pharmacological insights
which inform our ongoing or future clinical development plans for
these programs," said Dr. Michael
White, Chief Scientific Officer and Head of Research at
IDEAYA Biosciences.
IDEAYA is clinically evaluating IDE397, a potential
first-in-class small molecule inhibitor targeting MAT2A, in a Phase
1/2 clinical trial for patients having tumors harboring MTAP
deletion. The IDE397 clinical development strategy includes
ongoing IDEAYA-sponsored evaluation as monotherapy in select
indications and planned Amgen-sponsored evaluation in combination
with AMG 193, the Amgen investigational MTA-cooperative PRMT5
inhibitor, pursuant to a Clinical Trial Collaboration and Supply
Agreement. IDEAYA owns all commercial rights to IDE397 and
its MAT2A program.
IDEAYA is also clinically evaluating IDE161, a potential
first-in-class PARG inhibitor, in a Phase 1/2 clinical trial for
patients having tumors with HRD, including in BRCA1/2-mutant, ER+ /
Her2- breast cancer, which represents approximately 10% to 14% of
breast cancer. IDEAYA plans to initiate dosing of a first
patient in the Phase 1 dose escalation study in the first quarter
of 2023. IDEAYA owns or controls all commercial rights to
IDE161 and its PARG program, subject to certain economic
obligations under an exclusive, worldwide license with Cancer
Research UK / University of Manchester.
IDEAYA is, in collaboration with GSK, preclinically advancing
its Werner Helicase inhibitors for tumors with high microsatellite
instability (MSI), with development candidate selection targeted in
2023. IDEAYA is eligible to receive future development and
regulatory milestones, including up to $10
million aggregate through IND effectiveness – $3 million in connection with IND-enabling
studies and an additional $7 million
through IND effectiveness. Following selection of a
development candidate, GSK will lead clinical development for the
Werner Helicase program.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to the various presentations at the 2023 Annual
Meeting of AACR . Such forward-looking statements involve
substantial risks and uncertainties that could cause IDEAYA's
preclinical and clinical development programs, future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks
and uncertainties include, among others, the uncertainties inherent
in the drug development process, including IDEAYA's programs' early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, IDEAYA's ability to successfully
establish, protect and defend its intellectual property, the
effects on IDEAYA's business of the worldwide COVID-19 pandemic,
the ongoing military conflict between Russia and Ukraine, and other matters that could affect
the sufficiency of existing cash to fund operations. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's Annual
Report on Form 10-K filed on March 7,
2023 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-presentations-at-aacr-annual-meeting-2023-for-potential-first-in-class-synthetic-lethality-programs-ide397-mat2a-ide161-parg-and-werner-helicase-301770872.html
SOURCE IDEAYA Biosciences, Inc.